Valink Therapeutics

valinktx.com →

-90%

est. 2Y upside i

HealthcarePre-Seed

Discovering bispecific antibody drug-conjugates (BsADC) against cancer

Rank

#2262

Sector

Biotechnology

Est. Liquidity

~6Y

Data Quality

Data: Medium

Valink Therapeutics is a preclinical biotechnology company with a promising proprietary platform for bispecific antibody-drug conjugates in a high-growth oncology market.

Last updated: March 10, 2026

Bull (20%)+300%

Valink's proprietary V-gate™ approach and LiliumX™ platform successfully deliver first-in-class bispecific ADCs, with multiple programs advancing rapidly into clinical trials and securing a major licensing deal or partnership. This success, coupled with the strategic alliance with Nona Biosciences, drives a valuation of $240M, a 4x increase from the current estimated valuation.

Base (35%)+50%

Valink successfully advances one or two preclinical programs into Phase 1 clinical trials, demonstrating promising initial safety and efficacy data. The company secures a Series A funding round at a higher valuation, reaching approximately $90M, reflecting steady progress in a competitive but growing market.

Bear (45%)-80%

Valink faces significant challenges in preclinical development, including unexpected toxicity or efficacy issues, or struggles to secure further funding in a tightening biotech market. This leads to a down round or a significantly delayed pipeline, resulting in a valuation of $12M, wiping out most common stock value given the $20.5M in liquidation preferences.

Est. time to liquidity~6.0 years

Preference Stack Risk

severe

Investors hold $20.5M in liquidation preferences. In an exit at or below the estimated $60M valuation, common stock holders would receive little to nothing until investors recoup their investment.

Dilution Risk

high

As a preclinical company, Valink will require several more significant funding rounds to advance its pipeline, leading to substantial future dilution for existing shareholders.

Secondary Liquidity

none

Given its early stage, there is currently no active secondary market for Valink Therapeutics' shares.

Other — 4 roles

View all 4 open roles at Valink Therapeutics →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Valink Therapeutics's data — designed to show you've done your homework.

  • 1

    “Given the highly competitive landscape in bispecific ADCs, how does Valink's V-gate™ approach specifically differentiate its pipeline candidates from those being developed by larger incumbents like Seagen or Daiichi Sankyo?”

  • 2

    “With two oncology programs advancing into preclinical development, what are the key milestones Valink aims to achieve in the next 12-18 months, and what are the primary risks to hitting those timelines?”

  • 3

    “Considering the $20.5M in total funding and the preclinical stage, how is the company thinking about managing future dilution for employees, and what is the anticipated timeline for a potential liquidity event?”

Community

Valuation Sentiment

Our model estimates -90% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.